Mode
Text Size
Log in / Sign up
N/A Completed N=26

Five-Year Observation of Remicade Treatment for Plaque Psoriasis in Austria (Study P04900)

Source: ClinicalTrials.gov NCT00725452 ↗
Enrolled (actual)
26
Serious AEs
7.7%
Results posted
Sep 2011
Primary outcomePrimary: Number of Therapies That Were Applied as Induction, Maintenance, or Episodic Therapies After One Infusion of Infliximab — 7; 2; 1; 2 Therapies

Summary

Prospective, open-label-, 1-arm, multicenter observational study to determine the dose and interval of Infliximab infusions for subjects with plaque psoriasis.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Therapies That Were Applied as Induction, Maintenance, or Episodic Therapies After One Infusion of Infliximab
7; 2; 1; 2 —
SECONDARY
Mean Time Interval Between Infliximab Infusions During Maintenance Treatment Following Induction Therapy
49.25; 57.25; 59.67; 55.00; 56.00; 55.50 —
SECONDARY
Median Time Interval Between Infliximab Infusions During Maintenance Treatment Following Induction Therapy
56.00; 56.00; 56.00; 56.00; 56.00; 55.50 —
SECONDARY
Mean Dose of Infliximab
4.55; 4.66; 4.67; 4.58; 4.51; 4.41 —
SECONDARY
Median Dose of Infliximab
4.88; 5.00; 5.00; 5.00; 4.91; 4.71 —
SECONDARY
Mean Percent Change From Baseline in Body Surface Area (BSA) Involved With Psoriasis After Treatment With Infliximab
38.63; -11.17 —

Eligibility Criteria

Inclusion Criteria

  • According to the European Summary of Product Characteristics (SPC): Adult subjects with moderate-to-severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systematic therapy including cyclosporine, methotrexate, or Psoralen-ultraviolet-A light (PUVA).

Exclusion Criteria

  • According to the European SPC:
  • Subjects with tuberculosis or other severe infections such as sepsis, abscesses, and opportunistic infections.
  • Subjects with moderate-to-severe heart failure (New York Heart Association (NYHA) class III/IV).
  • Subjects with a history of hypersensitivity to Infliximab or to other murine proteins or to any of the excipients.
  • Subjects with elevated liver enzymes (>5 upper limit of normal (ULN)).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00725452). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search